Evidence map›Paper›PMID 25759592›Full record

ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2015

Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.

Orna Nitzan, Mazen Elias, Bibiana Chazan, Walid Saliba

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04735042 (Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.), which is not on this map. Cited by 184 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 7 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04735042 completedstarted 2020, after this paper: background citation

Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Ran2020Enrolled60Registered outcomes9Posted comparisons0ConditionsType 2 Diabetes, Urinary Tract InfectionsArmsEmpagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill
PMID 29446523PMID 27862830PMID 28769579PMID 20539810PMID 20937688PMID 23967406PMID 24567764PMID 25140306PMID 28588220PMID 28622967PMID 29520146other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 7 syntheses or guidelines pooled it, 340 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Orna NitzanInfectious Disease Unit, Ha'emek Medical Center, Afula, Israel ; Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel ; Infectious Disease Unit, Padeh-Poriya Medical Center, Afula, Israel.
Mazen EliasBruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel ; Department of Internal Medicine C, Ha'emek Medical Center, Afula, Israel.
Bibiana ChazanInfectious Disease Unit, Ha'emek Medical Center, Afula, Israel ; Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Walid SalibaBruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel ; Department of Internal Medicine C, Ha'emek Medical Center, Afula, Israel.
Technion – Israel Institute of Technology · ILEmek Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tract infections are more common, more severe, and carry worse outcomes in patients with type 2 diabetes mellitus. They are also more often caused by resistant pathogens. Various impairments in the immune system, poor metabolic control, and incomplete bladder emptying due to autonomic neuropathy may all contribute to the enhanced risk of urinary tract infections in these patients. The new anti-diabetic sodium glucose cotransporter 2 inhibitors have not been found to significantly increase the risk of symptomatic urinary tract infections. Symptoms of urinary tract infection are similar to patients without diabetes, though some patients with diabetic neuropathy may have altered clinical signs. Treatment depends on several factors, including: presence of symptoms, severity of systemic symptoms, if infection is localized in the bladder or also involves the kidney, presence of urologic abnormalities, accompanying metabolic alterations, and renal function. There is no indication to treat diabetic patients with asymptomatic bacteriuria. Further studies are needed to improve the treatment of patients with type 2 diabetes and urinary tract infections.

Indexed as

diabetes mellitusdiagnosismanagementprevalenceurinary tract infection

Identifiers

PMID25759592
PMCPMC4346284
OpenAlexW2067775744

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.